Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2015
At a glance
- Drugs ITX 5061 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 05 Oct 2015 Results published in the Liver Transplantation.
- 05 Nov 2013 Results presented at the American Association for the Study of Liver Disease (AASLD) meeting, according to an iTherX Pharmaceuticals media release.
- 22 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.